Sandoz targets doubling sales by 2035, 30%+ EBITDA margin

Sandoz Group announced a long-term target to more than double net sales by 2035 versus 2025 and achieve a central EBITDA margin above 30%. This is a corporate guidance update, not a market-moving event, but signals management confidence in growth and profitability. The target is aspirational and subject to execution risks, including biosimilar competition and pricing pressures.